Real-world Comparative Effectiveness of Dabigatran Versus Vitamin K Antagonist
Status: | Completed |
---|---|
Conditions: | Atrial Fibrillation |
Therapuetic Areas: | Cardiology / Vascular Diseases |
Healthy: | No |
Age Range: | 18 - Any |
Updated: | 4/6/2017 |
Start Date: | February 12, 2016 |
End Date: | March 1, 2016 |
Real-world Comparative Effectiveness of Dabigatran Versus VKA
To obtain a better understanding on the comparative effectiveness of dabigatran versus
Vitamin K antagonist (VKA) for stroke prevention in patients with Non-valvular atrial
fibrillation (NVAF) in a real-life setting.
Vitamin K antagonist (VKA) for stroke prevention in patients with Non-valvular atrial
fibrillation (NVAF) in a real-life setting.
Inclusion Criteria:
- Non-valvular atrial fibrillation will be defined as the occurrence of 2 or more
inpatient or outpatient claims with ICD-9 427.31 (International Classification of
Disease, Ninth Revision, Clinical Modification) as the diagnosis code at any time in
the patient's data history prior to inclusion
- Patients will be required to have 180 days of enrollment for the assessment of
baseline characteristics
- CHA2DS2-Vasc (Diabetes mellitus; S2: prior Stroke or TIA or Thromboembolism; V:
Vascular disease; A: Age 65-74 years; Sc: Sex category ) score ≥2 during the 180 days
prior to index dabigatran use baseline period
Exclusion Criteria:
- Patients <18 years of age
- Patients with valvular Atrial fibrillation
- Pregnancy
- Malignant cancers
- Transient cause of Atrial fibrillation
- Patients with Venous thromboembolism (pulmonary embolism or Deep Vein Thrombosis)
- Patients with major surgery defined as hip or knee replacement
- Prescriptions of Oral anticoagulants (OACs) {apixaban, warfarin, dabigatran,
rivaroxaban} before index date
- Prescription of more than one OAC on the index date
- Patient with any of the events defined in the composite endpoint
We found this trial at
1
site
Click here to add this to my saved trials